Health‐related quality of life outcomes in PARAGON‐HF

Chandra, A. et al. (2022) Health‐related quality of life outcomes in PARAGON‐HF. European Journal of Heart Failure, 24(12), pp. 2264-2274. (doi: 10.1002/ejhf.2738) (PMID:36394533)

[img] Text
285933.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.



Aims: Heart failure (HF) is associated with poor health-related quality of life (HRQL). Patients with HF with preserved ejection fraction (HFpEF) have similar HRQL impairment as those with reduced ejection fraction. This study describes the impact of sacubitril/valsartan on HRQL in patients with HFpEF enrolled in the PARAGON-HF trial. Methods and Results: Patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQol (EQ) at randomization, 4 months, 8 months, and annually thereafter. Changes in HRQL scores were evaluated using repeated measures models adjusted for treatment, baseline values and region. The pre-specified principal efficacy assessment was at 8 months at which time patients randomized to sacubitril/valsartan had borderline higher KCCQ-Clinical Summary score (CSS) with LSM adjusted difference of 1.0 (95% CI 0.0, 2.1); p=0.051. Including all visits up to 36 months, the LSM difference in KCCQ-CSS favored sacubitril/valsartan with average adjusted difference of 1.1 (95% CI 0.1, 2.0); p=0.034. Patients treated with sacubitril/valsartan had greater odds of clinically meaningful improvement (≥5-point increase) in KCCQ-CSS (OR 1.31; 95% CI 1.06, 1.61) at 8 months. At 8 months, there was no significant difference in the EQ visual analogue scale between the treatment arms, but sacubitril/valsartan was associated with higher EQ-5D utility score (US-based) with LSM adjusted difference of 0.01 (95% CI 0.00, 0.02); p=0.019. Conclusion: Compared with valsartan, sacubitril/valsartan has a borderline benefit on KCCQ-CSS at 8 months in patients with HFpEF. This benefit became more significant when data from all visits up to 36 months were included. This modest overall benefit was also supported by greater odds of patients reporting a clinically meaningful improvement in HRQL with sacubitril/valsartan.

Item Type:Articles
Additional Information:The PARAGON-HF study was funded by Novartis.
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., Zile, M. R., Desai, A. S., Pfeffer, M. A., McMurray, J. J.V., Solomon, S. D., and Lewis, E. F.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:European Journal of Heart Failure
ISSN (Online):1879-0844
Published Online:17 November 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in European Journal of Heart Failure 24(12): 2264-2274
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record